BiPar Sciences presents interim phase 2 results for PARP inhibitor BSI-201 at San Antonio Breast Cancer Symposium

Cancer Biol Ther. 2009 Jan;8(1):2-3. doi: 10.4161/cbt.8.1.7613.
No abstract available

Publication types

  • News

MeSH terms

  • Breast Neoplasms / drug therapy*
  • Enzyme Inhibitors / therapeutic use*
  • Female
  • Humans
  • Poly(ADP-ribose) Polymerase Inhibitors*
  • Texas

Substances

  • Enzyme Inhibitors
  • Poly(ADP-ribose) Polymerase Inhibitors